Investing.com - Monopar Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that was in line with expectations.
Monopar Therapeutics announced earnings per share of $-0.190 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.217 on revenue of $0.00.
Monopar Therapeutics shares are up 25.4% from the beginning of the year, still down 36.59% from its 52 week high of $5.20 set on November 11, 2021.
Monopar Therapeutics follows other major Healthcare sector earnings this month
Monopar Therapeutics's report follows an earnings beat by UnitedHealth on October 14, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on October 18 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar